FGFR2 is a member of the fibroblast growth factor receptor family which play a role in mitogenesis and differentiation. FGFR2 is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, and mutations in FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis (1). FGFR2 is required for early postimplantation development between implantation and the formation of the egg cylinder (2). FGFR2 contributes to the outgrowth, differentiation, and maintenance of the inner cell mass.
K-SAM, BFR-1, CEK3, ECT1, TK14, TK25, CD332, JWS, TK14
1. Arman, E.: Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc. Nat. Acad. Sci. 95: 5082-5087, 1998.
2. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am. J. Hum. Genet. 70: 472-486, 2002.
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Gudernova Iva et al., Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short-stature syndromes. Human Molecular Genetics October 2015 10.1093/hmg/ddv441
Krejci Pavel et al., Receptor Tyrosine Kinases Activate Canonical WNT/β-Catenin Signaling via MAP Kinase/LRP6 Pathway and Direct β-Catenin Phosphorylation PLoS One April 2012 10.1371/journal.pone.0035826
Ho K et al., Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing Current Medicinal Chemistry April 2013 10.2174/0929867311320100001
AKT/PKB Pathway, Angiogenesis, Cancer, ERK/MAPK Pathway, Receptor Tyrosine Kinases